I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ASRS 2024

-
Coming soon
06:00 AM
Duration 8mins Stockholm, Sweden
Assessing the Strength of Clinical Practice Guidelines for Managing Diabetic Macular Edema- a Systematic Literature Review
McAllister M, Ko S, Tabano D, Bawa K, Mearns E, Faux N, Patel S, Spicer G, Martinez A, Lim J
09:35 AM
Duration 3mins Stockholm, Sweden
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Jhaveri C, Dang S, Amador M, Dieckmann A, Gibson K, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A
Duration 3mins Stockholm, Sweden
Greater reduction in hard exudates with faricimab▼ vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials
Ip M, Goldberg R, Amador M, Dinah C, Gibson K, Glittenberg C, Maunz A, O'Leary O, Rahimy E, Uschner D
08:40 AM
09:15 AM
11:00 AM
Duration 3mins Stockholm, Sweden
Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle
Pieramici D, Pearce I, Campochiaro P, Chang M, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo C
06:42 AM
Duration 4mins Stockholm, Sweden
Pigment Epithelial Detachment Outcomes With Faricimab▼ vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Ambresin A, Khanani A, Lai T, Lim J, London N, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M
12:32 PM
Duration 6mins Stockholm, Sweden
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Loewenstein A, Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z
08:30 AM
Duration 3mins Stockholm, Sweden
Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With nAMD in the UK: 1-Year Results From the FARWIDE-nAMD Study
Pearce I, Talks J, de Salvo G, Patel P, de Silva S, Gale R, McKibbin M, Varma D, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P
08:35 AM
10:55 AM
Duration 4mins Stockholm, Sweden
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Dinah C, Dodds M, Arrisi P, Paris L, Lake A, Nielsen P, Holdsworth J, Saffar I, Chi G